Q-omics provides the consensus-scored RPL36AP16 profile across patient tissues and cancer cell-line models. RPL36AP16 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL36AP16 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, RPL36AP16 RNA expression shows 8,935 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight ACC, COAD, and OV as cancer lineages where RPL36AP16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36AP16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36AP16 survival associations across molecular data types. RPL36AP16 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36AP16 RNA expression–survival associations across cancer types. High RPL36AP16 expression shows unfavorable associations in ACC, STAD, CHOL, SARC and UCEC, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify ACC as the clearest survival context for RPL36AP16 RNA expression.
This table summarizes RPL36AP16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36AP16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36AP16 shows lower tumor expression in THCA and higher tumor expression in COAD, BLCA, HNSC, READ and PRAD. The COAD box plot shows higher RPL36AP16 RNA expression in tumor versus normal tissue (log2 FC = +0.492, t-test p < 0.001).
This table shows molecular features associated with RPL36AP16 in patient tissues and cancer cell lines. In patient samples, RPL36AP16 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
